DAPAGLIFLOZIN
Generic: DAPAGLIFLOZIN
Aurobindo Pharma LimitedManufacturer
ORALRoute
DAPAGLIFLOZINActive Substance
2026-04-06Original Approval
DAPAGLIFLOZIN is FDA application ANDA211468, sponsored by AUROBINDO PHARMA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Top Reported Reactions
1
DEATH
4,335 reports
2
ACUTE KIDNEY INJURY
1,597 reports
3
DYSPNOEA
1,367 reports
4
OFF LABEL USE
1,365 reports
5
DIARRHOEA
1,295 reports
6
NAUSEA
1,284 reports
7
FATIGUE
1,274 reports
8
DIZZINESS
1,188 reports
9
VOMITING
1,144 reports
10
DIABETIC KETOACIDOSIS
1,030 reports